Get the Stockscreener App
57.71
0.54%
0.31
After Hours:
57.64
-0.07
-0.12%
Xenon Pharmaceuticals Inc stock is traded at $57.71, with a volume of 1.22M.
It is up +0.54% in the last 24 hours and up +1.51% over the past month.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
See More
Previous Close:
$57.40
Open:
$57.89
24h Volume:
1.22M
Relative Volume:
0.91
Market Cap:
$5.58B
Revenue:
$7.50M
Net Income/Loss:
$-345.91M
P/E Ratio:
-13.24
EPS:
-4.3602
Net Cash Flow:
$-280.51M
1W Performance:
+5.83%
1M Performance:
+1.51%
6M Performance:
+49.28%
1Y Performance:
+53.73%
1-Day Range:
$56.90
$58.53
1-Week Range:
$53.80
$58.53
52-Week Range:
$28.19
$63.95
Xenon Pharmaceuticals Inc Stock (XENE) Company Profile
Name
Xenon Pharmaceuticals Inc
Sector
Industry
Phone
(604) 484-3300
Address
200 - 3650 GILMORE WAY, BURNABY
Compare XENE vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XENE
Xenon Pharmaceuticals Inc
|
57.71 | 5.55B | 7.50M | -345.91M | -280.51M | -4.3602 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-24-26 | Initiated | Wolfe Research | Outperform |
| Sep-03-25 | Resumed | Wells Fargo | Overweight |
| May-07-25 | Initiated | Chardan Capital Markets | Buy |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Oct-01-24 | Initiated | H.C. Wainwright | Buy |
| Jan-04-24 | Initiated | Citigroup | Buy |
| Dec-08-23 | Initiated | Robert W. Baird | Outperform |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Apr-25-23 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-14-22 | Initiated | Goldman | Buy |
| Dec-12-22 | Initiated | Cowen | Outperform |
| Nov-28-22 | Initiated | Wells Fargo | Overweight |
| Oct-19-22 | Initiated | Raymond James | Outperform |
| Aug-29-22 | Initiated | BofA Securities | Buy |
| Jul-21-22 | Initiated | JP Morgan | Overweight |
| Oct-28-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-02-20 | Initiated | SVB Leerink | Outperform |
| Jul-21-20 | Initiated | Needham | Buy |
| Jun-01-20 | Resumed | Jefferies | Buy |
| Mar-25-20 | Initiated | Wedbush | Outperform |
| Jan-08-20 | Initiated | William Blair | Outperform |
| Sep-20-19 | Initiated | Guggenheim | Buy |
| Aug-08-18 | Reiterated | Stifel | Buy |
| Mar-13-17 | Initiated | Jefferies | Buy |
| Oct-21-16 | Initiated | Stifel | Buy |
| Sep-26-16 | Initiated | Guggenheim | Buy |
| Apr-14-16 | Reiterated | Jefferies | Buy |
| Oct-30-15 | Resumed | Jefferies | Buy |
| Dec-02-14 | Initiated | Canaccord Genuity | Buy |
View All
Xenon Pharmaceuticals Inc Stock (XENE) Latest News
XENON PHARMACEUTICALS INC (NASDAQ:XENE) Breakout Setup Combines 9/10 Technical Strength with 9/10 Consolidation Quality - ChartMill
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Seven new Xenon hires get stock awards priced at $56.04 - Stock Titan
Jennison Associates LLC Boosts Stock Position in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Pictet Asset Management Holding SA Cuts Position in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Xenon to Report Q1 2026 Financial Results on May 7, 2026 - The Manila Times
May 7 after the bell: Xenon to give Q1 update, host webcast - Stock Titan
Xenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE) - MarketBeat
Xenon spikes, Theravance sinks after phase III readouts in March - BioWorld News
Xenon Pharmaceuticals Highlights Strong Phase III Azetukalner Data, Q3 NDA Plans at Bloom Burton Conference - MarketBeat
XENE Price Today: Xenon Pharmaceuticals Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Xenon Pharmaceuticals Reports Positive Phase 3 Azetukalner Results - HarianBasis.co
Peregrine Capital Management LLC Invests $7.84 Million in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Xenon Pharmaceuticals Inc (XENE) Looking At a $2 Billion Opportunity Here - Yahoo Finance
Xenon's Phase 3 Supports A 'Buy' Despite Its Premium (NASDAQ:XENE) - Seeking Alpha
[ARS] Xenon Pharmaceuticals Inc. SEC Filing - Stock Titan
Xenon Pharmaceuticals (XENE) 2026 proxy details board elections and new equity plan - Stock Titan
Analysts Are Bullish on Top Healthcare Stocks: Xenon (XENE), Biogen (BIIB) - The Globe and Mail
Needham Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating, Maintains Target Price $80 - Moomoo
RBC Raises Xenon Price Target, Cites Phase III Optimism for Epilepsy Drug - MSN
Stifel sees Xenon Pharmaceuticals stock reaching $2B in peak sales - Investing.com
Xenon Pharmaceuticals (XENE) Reports Positive Phase 3 Study Resu - GuruFocus
Xenon Pharma’s azetukalner shows 53% seizure reduction in trial By Investing.com - Investing.com South Africa
Xenon presents positive epilepsy drug trial data at AAN meeting - Investing.com
Xenon presents positive epilepsy drug trial data at AAN meeting By Investing.com - Investing.com Canada
Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting - The Manila Times
Xenon Pharmaceuticals Reports Positive Phase 3 X-TOLE2 Study Results for Azetukalner in Focal Onset Seizures at AAN 2026 - Quiver Quantitative
Xenon Pharma’s azetukalner shows 53% seizure reduction in trial - Investing.com UK
Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results - GlobeNewswire
Xenon to Present at Upcoming Investor Conferences - Sahm
Xenon Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:XENE) - MarketBeat
Xenon to Spotlight Neurology Pipeline at Series of 2026 Investor Conferences - TipRanks
Xenon Expands 2025 Inducement Equity Incentive Plan - The Globe and Mail
Xenon Pharmaceuticals Amends 2025 Inducement Equity Incentive Plan for Nasdaq Compliance and Employee Attraction 10 - Minichart
Xenon Pharmaceuticals (XENE) boosts 2025 inducement equity plan share reserve - Stock Titan
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Certain Restricted Stock Units of Xenon Pharmaceuticals Inc. are subject to a Lock-Up Agreement Ending on 10-APR-2026. - marketscreener.com
Certain Stock Options of Xenon Pharmaceuticals Inc. are subject to a Lock-Up Agreement Ending on 10-APR-2026. - marketscreener.com
Certain Common Shares of Xenon Pharmaceuticals Inc. are subject to a Lock-Up Agreement Ending on 10-APR-2026. - marketscreener.com
Published on: 2026-04-09 12:46:57 - baoquankhu1.vn
Xenon Pharmaceuticals to present azetukalner epilepsy data at AAN By Investing.com - Investing.com Australia
Xenon Pharmaceuticals to present azetukalner epilepsy data at AAN - Investing.com
Xenon Pharmaceuticals Inc Stock (XENE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):